Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609)

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|122|19|3032-3040

ISSN： 0008-543x

Source： CANCER, Vol.122, Iss.19, 2016-10, pp. : 3032-3040

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor‐2‐positive breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 4, 2018-02 ,pp. : 844-853

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 642-651

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience

By  

Oncology Research and Treatment, Vol. 35, Iss. 12, 2012-10 ,pp. : 740-745

Karger

Access to resources Recommend Favorite

Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cells: Regulation of Expression of Cancer-Related Genes by Estradiol and Tamoxifen

By  

Current Signal Transduction Therapy, Vol. 3, Iss. 1, 2008-01 ,pp. : 7-21

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 111-116

Bentham Science Publishers

Access to resources Recommend Favorite